Combination therapy of hypertension - is it time for polypill?
https://doi.org/10.18705/1607-419X-2009-15-4-458-461
Abstract
Results of multiple clinical studies confirmed the benefit of early start of combination antihypertensive therapy for decrease of cardiovascular risk. The paper discusses the advantages and disadvantages of fixed combinations and fixed in one blister combinations.
About the Author
Y. V. Sviryaev
Almazov Federal Heart, Blood and Endocrinology Centre, St Petersburg
Russian Federation
Russian Federation
References
1. Chobanian A.V., Bakris G.L., Black H.R. et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure // Hypertension. - 2003. - Vol. 42. - P.1206-1252.
2.
3. Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Hypertension. - 2007. - Vol. 25. - P. 1105-1187.
4.
5. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов // Кардиоваск. тер. и профилакт. (Прил. 2). - 2008. - Т. 7, № 6.
6.
7. Karatzas N.B., Leer J. Metoprolol versus thiazide diuretics in hypertension: morbidity results from the MAPHY Study // Hypertension. - 1991. - Vol. 17. - P. 579-588.
8.
9. Hansson L., Zanchetti A., Garruthers S.G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial // Lancet. - 1998. - Vol. 351. - P. 1755-1762.
10.
11. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) // JAMA. - 2002. - Vol. 288. - P. 2981-2897.
12.
13. Dahlof B., Sever P.S., Poulter N.R. et al. for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipin adding perindopril as required versus atenolol adding bendroflume-thiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial // Lancet. - 2005. - Vol. 366. - P. 895-906.
14.
15. Calhoun D.A., Jones D., Textor S. et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research // Circulation. - 2008. - Vol. 117. - P. e510-e526.
16.
17. Hajjar I., Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000 // JAMA. - 2003. - Vol. 290. - P.199-206.
18.
19. Lloyd-Jones D.M., Evans J.C., Larson M.G. et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community // Hypertension. - 2000. - Vol. 36. - P. 594-599.
20.
21. Dusing R. Overcoming barriers to effective blood pressure control in patients with hypertension // Curr. Med. Res. Opin. - 2006. - Vol. 22, № 8. - P. 1545-1553.
22.
23. Frishman W.H., Hainer J.W., Sugg J. M-FACT Study Group. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT) // Am. J. Hypertens. - 2006. - Vol. 4. - Р. 388-395.
24.
25. Mourad J.J ., Waeber B ., Zannad F. et al.: investigators of the STRATHE trial . Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach // J. Hypertens. - 2004. - Vol. 22, № 12. - Р. 2379-2386.
26.
27. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80 % // BMJ. - 2003. - Vol. 326, № 7404. - P. 1419.
28.
29. Леонова Л.Д., Белоусов Ю.Б. Результаты исследования ПИФАГОР // Качественная клиническая практика. - 2002. - № 5. - С. 17-22.
30.
31. Эйдельман С.Е. Фармакоэпидемиология артериальной гипертензии в Санкт-Петербурге на примере Петроградского района // Артериальная гипертензия. - 2002. - Т. 8, № 6. - С. 212-216;
32.
33. Беленков Ю.Н., Мареев В.Ю. Эналаприл Плюс Индапамид в лечении АГ: оценка эффективности и безопасности Рациональной Фармакотерапии (ЭПИГРАФ). Первые результаты Российского многоцентрового исследования // Сердце. - 2005. - Т. 2, № 4. - С. 21.
34.
35. Беленков Ю.Н., Агеев Ф.Т., Бойцов С.А. и др. Эналаприл Плюс Индапамид в лечении АГ: оценка эффективности и безопасности Рациональной Фармакотерапии. Применение нефиксированной комбинации Эналаприла и Индапамида (Энзикс). Дизайн и основные результаты исследования ЭПИГРАФ-2 // Сердце. - 2005. - Т. 4, № 4. - C. 3-10.
36.
37. Свиряев Ю.В., Звартау Н.Э., Ротарь О.П. и др. Новые возможности улучшения копплаентности - результаты открытого исследования приверженности больных к лечению фиксированной в одном блистере комбинаций эналаприла и индапамида // Артериальная гипертензия. - 2006. - Т. 12, № 3. - С. 262-267.
Review
For citations:
Sviryaev Y.V. Combination therapy of hypertension - is it time for polypill? "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2009;15(4):458-461. (In Russ.) https://doi.org/10.18705/1607-419X-2009-15-4-458-461
Views:
784
Email this article 